Canada OKs Pfizer COVID-19 Booster For Kids Aged 5-11 Years
Canada's health ministry authorized the use of Pfizer Inc (NYSE: PFE) and BioNTech SE's (NASDAQ: BNTX) COVID-19 vaccine as a booster for children 5 - 11 years old at least six months after their initial two doses.-
The 10 mcg dose was authorized, and this is the first COVID-19 vaccine authorized as a booster dose in this age group.
The authorization for a booster shot was granted after a thorough, independent review of the vaccine, which provides "an option to restore their child's protection against COVID-19, especially those at high risk of severe illness," the health ministry wrote on Twitter.
Also Read: Biden Administration To Stop Purchasing COVID-19 Solutions By End Of 2022.
Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccine is authorized only as a primary series for children 6 - 11 years of age, using a 50 mcg dose, and for children six months to 5 years of age, using a 25 mcg dose.
Booster doses of Moderna Spikevax (50 mcg) COVID-19 vaccine are authorized only for individuals 18 and older.
In moderate to severely immunocompromised children, the Canadian authority recommends a primary series of three doses administered at least 4 to 8 weeks apart for both mRNA vaccines.
Price Action: BNTX shares closed at $147.92, and PFE stock closed at $49.15 on Friday.
See more from Benzinga
Biden Administration To Stop Purchasing COVID-19 Solutions By End Of 2022
Sanofi Earns Price Target Cut After Stopping Breast Cancer Drug Trial
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.